tailieunhanh - Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nabpaclitaxel therapy in metastatic pancreatic cancer

There is no established second-line treatment after failure of gemcitabine plus nab-paclitaxel (GnP) therapy for metastatic pancreatic cancer (MPC). The purpose of this study was to evaluate the efficacy and tolerability of the modified FOLFIRINOX (mFFX) as a second-line therapy for MPC and to investigate prognostic factors for survival. | Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nabpaclitaxel therapy in metastatic pancreatic cancer

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN